Cargando…

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer

PURPOSE: To assess the feasibility and utility of circulating tumor DNA (ctDNA) by amplicon-based next-generation sequencing (NGS) analysis in the daily clinical setting in a cohort of patients with advanced non–small-cell lung cancer (NSCLC), as an alternative approach to tissue molecular profiling...

Descripción completa

Detalles Bibliográficos
Autores principales:	Remon, Jordi, Lacroix, Ludovic, Jovelet, Cecile, Caramella, Caroline, Howarth, Karen, Plagnol, Vincent, Rosenfeld, Nitzan, Morris, Clive, Mezquita, Laura, Pannet, Chloe, Ngocamus, Maud, Le Pechoux, Cecile, Adam, Julien, Grecea, Alina-Miruna, Planchard, David, Vassal, Gilles, Benitez, Jose Carlos, Gazzah, Anas, Green, Emma, Soria, Jean-Charles, Besse, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Original Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446523/ https://www.ncbi.nlm.nih.gov/pubmed/32914037 http://dx.doi.org/10.1200/PO.18.00211

Ejemplares similares

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
por: Remon, Jordi, et al.
Publicado: (2020)

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report
por: Enrico, Diego, et al.
Publicado: (2020)

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
por: Geraud, Arthur, et al.
Publicado: (2020)

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer
por: Schernberg, Antoine, et al.
Publicado: (2018)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
por: Botticella, Angela, et al.
Publicado: (2019)

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients
por: Boros, Angela, et al.
Publicado: (2017)

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer
por: Jovelet, Cécile, et al.
Publicado: (2017)

Correction: EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2019)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2018)

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
por: Recondo, Gonzalo, et al.
Publicado: (2020)

Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease
por: Herrera-Gómez, Ruth Gabriela, et al.
Publicado: (2022)

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients
por: Koeppel, Florence, et al.
Publicado: (2017)

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
por: Gazzah, Anas, et al.
Publicado: (2013)

Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer
por: Péchoux, Cecile Le, et al.
Publicado: (2013)

Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report
por: Aldea, Mihaela, et al.
Publicado: (2022)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
por: Remon, Jordi, et al.
Publicado: (2017)

Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
por: Remon, Jordi, et al.
Publicado: (2017)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

(18)F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data
por: Besson, Florent L., et al.
Publicado: (2020)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
por: Park, Wungki, et al.
Publicado: (2019)

A long-read amplicon approach to scaling up the metabarcoding of lichen herbarium specimens
por: Gueidan, Cécile, et al.
Publicado: (2022)

Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Evolving target volume concepts in locally advanced non-small cell lung cancer
por: Nestle, Ursula, et al.
Publicado: (2021)

Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Pritchett, Michael A., et al.
Publicado: (2019)

Combined bacterial and fungal targeted amplicon sequencing of respiratory samples: Does the DNA extraction method matter?
por: Angebault, Cécile, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
por: Tagliamento, Marco, et al.
Publicado: (2022)

PacBio amplicon sequencing for metabarcoding of mixed DNA samples from lichen herbarium specimens
por: Gueidan, Cécile, et al.
Publicado: (2019)

Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
por: Remon, Jordi, et al.
Publicado: (2016)

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
por: Remon, J., et al.
Publicado: (2018)

Immunotherapy in other thoracic malignancies and uncommon populations
por: Remon, Jordi, et al.
Publicado: (2021)

Thoracic radiotherapy in small cell lung cancer—a narrative review
por: Levy, Antonin, et al.
Publicado: (2021)

Systematic review of phase‐I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research
por: Felix, Arthur, et al.
Publicado: (2021)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study
por: Bayle, Arnaud, et al.
Publicado: (2023)

Integrin-α(V)-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade
por: Malenica, Ines, et al.
Publicado: (2021)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6vesatjh08ne08fnepu4v5gl68